GlassScriptPhysician profile
Karen E Zagar
NPI 1902889587
$22,723.78
in general payments reported to CMS, 2019-2025
49 companies · $3,619 in 2025
The $3,619 reported for 2025 was more than what 81% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,659 · 2020: $2,288 · 2021: $3,069 · 2022: $3,425 · 2023: $3,189 · 2024: $4,475 · 2025: $3,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $400 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,765.32 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $400.00 |
| Education | $118.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,256.89 | 2019-2025 | Tavneos, Enbrel, Evenity |
| Abbvie INC. | $3,142.17 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $1,776.46 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,612.18 | 2019-2025 | Benlysta |
| Pfizer INC. | $1,500.20 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,352.90 | 2019-2025 | Orencia |
| Ucb, INC. | $1,286.52 | 2019-2025 | Bimzelx, Cimzia |
| Mallinckrodt Hospital Products INC. | $1,280.12 | 2020-2025 | Acthar |
| Janssen Biotech, INC. | $1,177.68 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Radius Health, INC. | $732.76 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $730.72 | 2020-2025 | Ofev, Cyltezo |
| Lilly USA, LLC | $725.88 | 2019-2025 | Taltz, Zepbound, Mounjaro |
| Genzyme Corporation | $617.29 | 2019-2025 | |
| Horizon Therapeutics Plc | $603.63 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $428.25 | 2021-2025 | Saphnelo |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $389.60 | 2019-2025 | |
| Fresenius Kabi USA, LLC | $377.92 | 2023-2025 | Idacio, Tyenne |
| Genentech USA, INC. | $277.00 | 2019-2025 | Gazyva |
| Alexion Pharmaceuticals, INC. | $207.91 | 2021-2025 | Strensiq |
| Aurinia Pharma U.S., INC. | $171.99 | 2024-2025 | Lupkynis |
| Antares Pharma, INC. | $143.38 | 2019-2025 | Xyosted |
| Dexcom, INC. | $124.50 | 2022-2023 | Dexcom G6 Transmitter |
| Mallinckrodt Enterprises LLC | $123.41 | 2019 | |
| Novo Nordisk INC | $94.37 | 2023-2025 | Wegovy |
| Sandoz INC. | $73.90 | 2023-2024 | Hyrimoz |
| Corcept Therapeutics | $52.46 | 2024-2025 | Korlym |
| Ani Pharmaceuticals, INC. | $52.38 | 2022-2025 | Purified Cortrophin Gel |
| Pacira Therapeutics, INC. | $50.46 | 2019-2020 | |
| Ibsa Pharma INC. | $47.43 | 2024 | Tirosint, Licart, Flector |
| Bayer Healthcare Pharmaceuticals INC. | $36.83 | 2025 | |
| Organon LLC | $34.74 | 2024 | |
| Neurocrine Biosciences, INC. | $30.39 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $26.10 | 2024 | Crysvita |
| Mannkind Corporation | $25.88 | 2025 | |
| Verity Pharmaceuticals INC. | $24.57 | 2025 | Tlando |
| Hikma Pharmaceuticals USA | $23.45 | 2019 | |
| Recordati_rare_diseases_inc. | $23.19 | 2025 | Isturisa |
| Medexus Pharma, INC. | $22.48 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $20.87 | 2024 | Arcalyst |
| Exact Sciences Corporation | $17.73 | 2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $16.00 | 2025 | Intracept |
| Avion Pharmaceuticals | $11.19 | 2020 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Zagar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.